Modeled CA-125 KELIM™ in patients with stage III-IV high grade serous ovarian carcinomas treated in first-line setting with neo-adjuvant chemotherapy

For patients with stage III or IV high grade serous ovarian carcinomas treated with neoadjuvant chemotherapy with carboplatin – paclitaxel in first line setting (every 3 weeks or weekly), with the intent of a potential interval debulking surgery (disease in place when the chemotherapy is started). This model does not apply to patients treated in recurrent setting.

CA-125 KELIM™ is calculated with at least 3 CA-125 values measured within the first 100 days (or less) after chemotherapy start.

For scientific studies ≥ 2 patients, the website team should be contacted at

Tutorial video

Other resources